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ABSTRACT:
Innovative  therapies  are  needed  for  advanced  Non-­Small  Cell  Lung  Cancer  (NSCLC).  We  
have  undertaken  a  genomics  based,  hypothesis  driving,  approach  to  query  an  emerging  potential  
that  epigenetic  therapy  may  sensitize  to  immune  checkpoint  therapy  targeting  PD-­L1/PD-­1  
interaction.  NSCLC  cell  lines  were  treated  with  the  DNA  hypomethylating  agent  azacytidine  
(AZA  -­  Vidaza)  and  genes  and  pathways  altered  were  mapped  by  genome-­wide  expression  and  
DNA  methylation  analyses.  AZA-­induced  pathways  were  analyzed  in  The  Cancer  Genome  Atlas  
(TCGA)  project  by  mapping  the  derived  gene  signatures  in  hundreds  of  lung  adeno  (LUAD)  and  
squamous  cell  carcinoma  (LUSC)  samples.  AZA  up-­regulates  genes  and  pathways  related  to  both  
innate  and  adaptive  immunity  and  genes  related  to  immune  evasion  in  a  several  NSCLC  lines.  
DNA  hypermethylation  and  low  expression  of  IRF7,  an  interferon  transcription  factor,  tracks  
with  this  signature  particularly  in  LUSC.  In  concert  with  these  events,  AZA  up-­regulates  PD-­L1  
transcripts  and  protein,  a  key  ligand-­mediator  of  immune  tolerance.  Analysis  of  TCGA  samples  
GHPRQVWUDWHVWKDWDVLJQL¿FDQWSURSRUWLRQRISULPDU\16&/&KDYHORZH[SUHVVLRQRI$=$LQGXFHG
immune  genes,  including  PD-­L1.  We  hypothesize  that  epigenetic  therapy  combined  with  blockade  
of  immune  checkpoints  –  in  particular  the  PD-­1/PD-­L1  pathway  -­  may  augment  response  of  
NSCLC  by  shifting  the  balance  between  immune  activation  and  immune  inhibition,  particularly  
LQDVXEVHWRI16&/&ZLWKORZH[SUHVVLRQRIWKHVHSDWKZD\V2XUVWXGLHVGH¿QHDELRPDUNHU
strategy  for  response  in  a  recently  initiated  trial  to  examine  the  potential  of  epigenetic  therapy  
to  sensitize  patients  with  NSCLC  to  PD-­1  immune  checkpoint  blockade.  
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INTRODUCTION
Innovative  strategies  are  needed  to  treat  the  world’s  
most   common   cause   of   cancer   death,   non-­small   cell  
lung  cancer  (NSCLC)  [1,  2].  Less  than  a  quarter  of  lung  
adenocarcinomas  (LUAD)  harbor  genetic  abnormalities  
for   which   targeted   therapies   have   been   derived.   Early  
responses   are   often   robust   for   these   but   are   generally  
followed  by  acquired  resistance  [3,  4].  Lung  squamous  
cell   carcinoma   (LUSC)   has   no   approved   targeted  
therapies   and   few   effective   chemotherapeutic   options  
EH\RQGWKH¿UVWOLQHRIWKHUDS\,QWKHFXUUHQWVWXG\ZH
offer  a  genomically  based,  hypothesis-­driving  analysis  to  
suggest  a  rationale  for  a  novel  combinatorial  therapeutic  
DSSURDFKWRHI¿FDFLRXVWUHDWPHQWVIRUDGYDQFHG16&/&
The  backdrop  for  the  present  study  comes  from  our  initial  
clinical  trials  in  our  Stand  up  to  Cancer  project  (SU2C)    in  
which  patients  with  advanced,  heavily-­pretreated  NSCLC  
received  a  form  of  “epigenetic  therapy”  combining  low  
doses   of      the  DNA  hypomethylating   agent   azacytidine  
(AZA   -­   Vidaza)   and   the   HDAC   inhibitor   entinostat  
[5].     Only   two  of  now  65  patients   treated   to  date  have  
had   RECIST   criteria   responses   to   this   therapy   alone,  
but   these  were  very  robust  and  durable  (5).  A  group  of  
patients  followed  for  8  to  26  months  responded  to  multiple  
different   therapeutic   regimens   given   subsequently,  
suggesting  a  “priming”  effect  of  epigenetic  therapy  (5).  
7ZHQW\¿YHSHUFHQWRI WKHVHSDWLHQWVZLWKERWK/8$'
and  LUSC  experienced  RECIST  criteria  responses  to  their  
subsequent  regimens.  These  subsequent  therapies  included  
not  only  standard  chemotherapies  but  also  immunotherapy  
targeting  the  PD-­1  immune-­checkpoint  which  when  given  
alone  has  yielded  responses  in  16  to  17%  of  patients  with  
advanced  NSCLC  [6-­8]  (Supp.  Fig.  1).  While  the  number  
of  patients  who  have  received  epigenetic  therapy  followed  
by   immune   checkpoint   blockade   is   small,   a   clinical  
trial  to  evaluate  potential  sensitization  to  PD-­1  immune  
checkpoint  blockade  with  epigenetic  therapy  in  patients  
with  NSCLC  has  now  begun.  
This   trial   will   be   biopsy   driven   and   offer   the  
opportunity   to   examine   hypotheses   generated   in   the  
present  pre-­clinical  work  in  order  to  develop  biomarker  
strategies.  In  this  regard,  one  of  the  key  therapy  agents  
being  employed  in  the  trial  is  AZA,  a  nucleotide  analog  
DNA  demethylating  agent  which  blocks   the  activity  of  
all   three   biologically   active   DNA   methyltransferases  
(DNMT’s)  and  also  triggers  degradation  of  these  proteins  
in   the   nucleus   [9,   10].   With   respect   to   sensitization  
potential  of  this  drug  for  immune  responses,  such  targeting  
of  DNMT’s  is  known  to  induce  increased  expression  of  
promoter  DNA  hypermethylated   cancer   testes   antigens  
and  also  is  reported  to  up-­regulate  other  individual  facets  
RIWKHWXPRULPPXQHVWLPXODWLQJSUR¿OHLQFOXGLQJPDMRU
histocompatibility  antigens,  and  transcription  factors  IRF7  
and    IRF5  [11-­16].  In  this  regard,  we  previously  reported  
that  elements  of  such  immune  pathway  activation  were  
produced  by  low  doses  of  DNA  demethylating  agents  in  a  
genomics  based,  pre-­clinical  approach  [17].  These  studies  
demonstrated  how  low  doses  of  AZA,  which  avoid  early,  
cytotoxic   and  off-­target   effects,   can  provide  a  memory  
for   a   “reprogramming”-­like   effect   on   hematopoietic  
and   selected   examples   of   solid   tumor   cells   [18].   We  
hypothesize  in  this  work  that  these  effects  may  underlie  the  
IDFWWKDWVLJQL¿FDQWO\ORZHULQJGRVHVRI'107LQKLELWRUV
in   the   clinic   may   account   for   the   markedly   decreased  
WR[LFLW\DQGVLJQL¿FDQWFOLQLFDOHI¿FDF\ZKLFKKDVOHGWR
FDA  approval  of  AZA  for  myelodysplasia  (MDS)  [19].          
Initially,  we  have  focused  our  pre-­clinical  studies  
IRUORZGRVH$=$RQ16&/&%\¿UVWGHULYLQJJHQRPLF
signatures   of   gene   expression   responses   and   DNA  
methylation   for   treated   NSCLC   lines,   we   observed   in  
most   cell   lines   a   complex,  multi-­faceted  up-­regulation,  
LQYROYLQJ KXQGUHGV RI JHQHV RI WKH LPPXQH SUR¿OH
of   these   cells   which   includes   the   target   of   immune  
checkpoint  therapy,  the  tumor  ligand  PD-­L1.  Moreover,  
using   this   extensive   genomic   signature,   we   have   been  
DEOH WRVSHFL¿FDOO\TXHU\KXQGUHGVRISULPDU\16&/&
samples   in   the   Cancer   Genome  Atlas   project   (TCGA)  
for   how   basal   expression   of   these   immune   genes   and  
related  DNA  methylation  events  group  lung  cancers.  We  
GH¿QHDVWDUNFOXVWHULQJRIVXEVHWVRISULPDU\/8$'DQG
LUSC  for  an  “immune  evasion”  signature,  which  relates  
highly  to  events  for  low  interferon  pathway  signaling  and  
includes  low  levels  of  PD-­L1  [20-­22].  Low  expression  of  
these  genes  closely  matches  those  up-­regulated  by  AZA  
treatment  of  the  NSCLC  cell  lines.  We  hypothesize  that  
WKHVHPD\ EH FDQFHUV ZKLFK ZRXOG EHQH¿W IURP$=$
priming   together  with   immune   checkpoint   therapy   and  
outline  a  signature  that  may  identify  predictive  biomarkers  
from  biopsies  forthcoming  in  the  current  trial.    
RESULTS
Clinical  Data
Six  patients  who  received  treatment  on  a  clinical  trial  
of  epigenetic  therapy  for  advanced  treatment-­refractory  
NSCLC   were   placed   on   trials   for   immunotherapy  
targeting  the  PD-­1/PD-­L1  immune  tolerance  checkpoint.  
Of   these   six   patients   three   have   experienced   durable  
partial  responses  to  immunotherapy  now  ongoing  for  14  
to  26  months,  and  the  other  two  had  stable  disease  lasting  
8.25  and  8.5  months.  (Supp.  Fig.  1,  Supp.  Table  1)  For  
comparison,   41-­46%   of  NSCLC   patients   on   these   two  
trials  of  immunotherapy  alone,  one  for  anti-­PD1  and  the  
other  for  anti-­PD-­L1  therapy,  passed  24  weeks  without  
progression  and16-­17%  had  durable  partial  response  rates  
[6-­8].
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Figure  1:  Azacytidine  alters  gene  expression  in  NSCLC  cell  lines  for  multiple  immune  related  pathways.  (A)  Top  panel:  
Gene  Set  Enrichment  Analysis  (GSEA)  for  pathways  up-­regulated  by  azacytidine.  Normalized  enrichment  scores  are  plotted  as  a  heat  map.  
Bottom  panel:  boxplot  showing  degree  of  demethylation  in  each  cell  line,  as  measured  by  the  difference  in  beta  values  between  the  AZA  
and  mock-­treated  cells  immediately  after  drug  withdrawal  and  7  days  later.  (B)  FACS  analysis  shows  increased  level  of  cell  surface  PD-­L1  
after  AZA  treatment  by  day  10  in  NSCLC  lines  H838  and  H1299.  (C)  to  (J)  AZA-­mediated  expression  changes  at  day  10  in  key  genes  from  
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AZA   Induced   Immune  Response   in  Non-­Small  
Cell  Lung  Cancer  Cell  Lines  
We  used  our  previously  validated  pre-­clinical  model  
to  examine  how  AZA  alters  expression  of  key  pathways  in  
NSCLC  cell  lines  [17].  Cells  were  treated  in  vitro  with  500  
nM  AZA  for  72  hours  then  harvested  immediately  after  
withdrawal  of  drug  and  again  one  week  later  for  genome  
wide  methylation   and   expression   studies.   To   the   point  
of   the   clinical   suggestion   that   epigenetic   therapy   may  
provide  sensitization  to  subsequent  immune-­checkpoint  
blockade,  we  agnostically  noted  that  one  or  more  of  the  
top  ten  pathways  emerging  for  each  cell  line  were  immune  
related.  The  genes  involved  are  important  to  the  interaction  
of   both   innate   and   adaptive   anti-­tumor   immunity.   As  
earlier  mentioned,  other  groups  have  described  the  ability  
of  AZA  to  up-­regulate  individual  immune  pathway  steps  
relative  to  assembly  of  major  histocompatibility  antigens  
(HLA  Class  I),  interferon  pathway  genes,  and  cancer-­testis  
antigens  [11-­16].  However,  our  current  analysis  reveals  a  
more  complex,  concordant,  broad  immune  gene  signature.  
Gene  Set  Enrichment  Analysis  showed  AZA  induced  up-­
regulation   of   multiple   immune-­related   pathways   in   a  
manner  roughly  correlating  to  the  degree  of  demethylation  
in  response  to  AZA  treatment  (Fig.  1A,  Supp.  Table  2).  
Each   of   these   components   has   a   demonstrated   role   in  
immune   tolerance   pathways   associated   with   immune  
checkpoints  and  immune  evasion.  Some  of  these  genes  
KDYH ORZ H[SUHVVLRQ DVVRFLDWHG ZLWK FDQFHUVSHFL¿F
promoter  region  DNA  hyper-­methylation,  and  increased  
expression   after   treatment   with   DNA   demethylating  
drugs  [11,  12].  In  this  regard,  it  is  noteworthy  that  when  
compared  to  normal  bronchial  epithelial  cells,  NSCLC  is  
known  to  exhibit  diminished  innate  immune  responses  to  
viral-­like  stimuli  involving  intertwined  pathways  of  cell-­
LQWULQVLFUHVSRQVHVWRLQIHFWLRQDQGLQÀDPPDWLRQ>@
Antigen  Presentation
A   key   step   in   tumor   recognition   and   killing   by  
cytotoxic  T-­cells  involves  recognition  of  peptides  derived  
IURP WXPRUVSHFL¿F DQWLJHQV RU XSUHJXODWHG VKDUHG
antigens  bound  to  HLA  Class  I  antigens  expressed  by  the  
tumor  cells  [23].  As  recognized  by  others,  AZA  increases  
expression  of  multiple   cancer   testes   antigens   including  
multiple  MAGE  family  genes,  whose  expression  has  been  
shown   to  be   suppressed  by  promoter  hypermethylation  
[14,  15]  (Fig.  1G).  AZA  up-­regulates  not  only  transcripts  
of   HLA   Class   I   antigens   but   also   a   series   of   genes  
including,  beta-­2-­microglobulin  (B2M),  CD58,  TAP1,  and  
the   immuno-­proteasome   subunits   PMSB9   and   PSMB8  
which  encode  proteins  required  for  endoplasmic  reticulum  
processing   of,   transport   to,   and   anchoring   to   the   cell  
surface  ,  and  recognition  of  surface  HLA  class  I  subunits  
>@ )LJ ':H ¿QG JHQHUDOO\ JRRG FRUUHODWLRQ
between  HLA  Class  I,  B2M,  CD58,  and  B7-­H3  transcripts  
DQGSURWHLQRQWKHFHOOVXUIDFHE\ÀRZF\WRPHWU\6XSS
Fig.  2).  Importantly,  mutations  potentially  contributing  to  
immune  evasion  have  been  described  in  HLA-­A  in  a  small  
percentage  of  LUSC  and  of  B2M  and  CD58  in  other  tumor  
types  [26,  27].
Type  I  and  II  Interferon  Signaling
A  second  key  issue  for  immune  cell  interaction  with  
tumor  cells  is  that,  in  vivo,  AZA  administration  to  tumor-­
bearing  mice  has  been  shown  to  induce  antigen  processing  
and  presentation  genes,  particularly  when  administered  
with  CpG  TLR9  agonists,  and  this  is  largely  attributed  to  
LQWHUIHURQȖSURGXFWLRQE\O\PSKRF\WHV>@:KLOHWKH
O\PSKRF\WHVSHFL¿FȖLQWHUIHURQLVQRWLQGXFHGLQ16&/&
lines  with  AZA  treatment,   there   is  up-­regulation  of   the  
LQWHUIHURQȖ UHFHSWRU IFNGR1)   as   well   as   of   multiple  
STAT  genes,  including  STAT1,  the  major  IFNGR1  signal  
transducer  (Fig.  1E).    
Programmed  Cell  Death  and  Viral  Defense
The   re-­expressed   genes   in   the   above   mentioned  
pathways  are  downstream  targets  of  interferon  response  
SDWKZD\VLQDIDVKLRQFORVHO\OLQNHGWRSURLQÀDPPDWRU\
and  viral  defense  responses  [28-­31].  In  turn,  triggering  of  
these  responses  can  have  both  tumor  repressing  activities,  
such   as   apoptosis,   or   tumor   promoting   events   and   this  
SDUDGR[KDVEHHQWHUPHG³WKHGXDOIDFH´RILQÀDPPDWLRQ
[29,  30,  32].  In  this  regard,  we  see  key  subsets  of  immune  
related  genes  that  are  up-­regulated  by  AZA  with  potential  
for   inhibiting   tumor   growth   including   IFI27,   which  
encodes  a  protein   triggering  apoptosis   in   late   stages  of  
chronic   viral   infection[33]   (Fig.   1F).   Simultaneously,  
there   is   down-­regulation   of   the   anti-­apoptotic   gene,  
MAVS,   a   change   which   accompanies   activation   of   the  
RIG  I  signaling  pathway  in  response   to  viral  challenge  
[30,   31,   34]   (Fig.   1H).   Downstream   events   in   viral  
response  include,  especially  in  line  H838,  simultaneous  
increases  for  expression  of  BIRC  family  autophagy  genes  
and   simultaneous  decreases   in   the   anti-­apoptotic  genes  
BCL2   and  BIRC5   (SURVIVIN)   [35]   (Fig.   1H).   Indeed,  
suppression  of  SURVIVIN   is   known   to  be   triggered  by  
the   viral   induction   of   IRAK3,   which   encodes   an   IL-­1  
receptor  associated  kinase  [36].  IRAK3  is,  again  in  H838  
cells,  up-­regulated  by  AZA  concordantly  with  the  death  
related   genes   mentioned   just   above   (Fig.   1H).   These  
dynamics  are  similar  to  those  for  colon  cancer  cells  where  
IRAK3   is   silenced   in   association  with   promoter-­region  
DNA  hypermethylation  and  when  reactivated  by  induced  




The  key  to  immune  checkpoint  therapy  is  antibody  
targeting  of  either  the  receptor  PD-­L1  on  immune  cells  
and   or   the   ligand   PD-­L1   on   tumor   cells   [6,   7,   23].   In  
the   clinical   trials   for   immune   check   point   blockade   to  
date   involving   NSCLC   patients,   a   subset   showed   no  
responses  when  their  tumors  did  not  express  cell  surface  
PD-­L1  [6,  7,  23].  In  this  regard,  when  treated  with  AZA,  
several  NSCLC  cell   lines   up-­regulate  PD-­L1,   not   only  
at  the  transcript  level  but  also  at  the  cell  surface  protein  
level  (Fig.  1B,  1C).  Notably,  this  AZA  increase  of  PD-­
L1  in  cell  lines  is  far  more  consistent  than  for  PD-­L2,  a  
second   dendritic   cell/macrophage   ligand   for   the   CTL  
PD-­1  receptor,  or  other  checkpoint   ligands  such  as  B7-­
H3   and  B7-­H4   (Fig.   1C).   Similarly,  CD80   and  CD86,  
the  ligands  for  CTLA4,  another  therapeutically  targeted  
immune  checkpoint   receptor,   are  not   altered   (Fig.  1C).  
PD-­L1  expression  in  tumor  cells  can  either  be  driven  by  
cell-­intrinsic  mechanisms  or  by  a  process  termed  adaptive  
UHVLVWDQFHWKURXJKLQWHUIHURQȖVLJQDOLQJDQGVXEVHTXHQW
Figure  2:  Genetic  knock  out  of  DNA  Methyltransferases  mimics  the  effects  of  azacytidine  mediated  immune  pathway  
up-­regulation.  Gene  expression  alterations  when  comparing  wild-­type  HCT116  colon  cancer  cells   to   their   isogenic  DNMT1  and  3B  
knockout  counterpart  (DKO).  The  gene  expression  differences  are  given  as  the  log2  ratio  of  expression  in  DKO  over  wild-­type  HCT116  
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)LJXUH,GHQWL¿FDWLRQRID]DF\WLGLQHXSUHJXODWHGWUDQVFULSWLRQIDFWRUVDQGLQWHUIHURQVLJQDOLQJUHODWHGJHQHVDQG
their  clustering  of  primary  Non-­Small  Cell  Lung  Cancer  in  TCGA.    $,GHQWL¿FDWLRQRIJHQHVLQ1RQ6PDOO&HOO/XQJ&DQFHU
cell  lines  with  low  basal  expression  with  high  basal  promoter  region  DNA  methylation  which  are  demethylated  and  re-­expressed  with  AZA  
WUHDWPHQW7KHUHGER[HQFRPSDVVHVJHQHVPHHWLQJWKHVHFULWHULDZKLFKDUHGHVFULEHGVSHFL¿FDOO\LQPHWKRGV$PRQJWKHVHIRF7,  a  key  
immune-­related  transcription  factor,  was  up-­regulated  in  multiple  cell  lines.  (B)  Pathways  up-­regulated  in  NSCLC  cell  lines  in  response  
to  AZA  are  enriched  for  IRF7  targets  as  determined  by  PScan  analysis  (-­log10  of  p-­values)  and  gene  set  enrichment  analysis.    (C)  Heat  
map  of  RNA-­Seq  expression  levels  in  primary  lung  cancers  from  TCGA  database  for  genes  4-­fold  or  more  induced  by  AZA  in  the  LUSC  
cell  line  H2170,  the  cell  line  with  the  greatest  degree  of  IRF7  up-­regulation.  Top  bar:  red  indicates  LUAD  and  orange  indicates  LUSC  
samples.  Genes  used  in  the  heat  map  are  listed  in  supplemental  table  4.  (D)  Bar  panels  show  expression  of  PD-­L1  and  IRF7LQ¿YHTXDQWLOH
intervals  (red  for  lower  and  green  for  higher  expression).    Heat  map  immediately  below  IRF7H[SUHVVLRQEDUVKRZVFRUUHVSRQGLQJ,Q¿QLXP
platform  DNA-­methylation  levels  (Z-­scores,  red  for  more  and  green  for  less  methylated)  across  the  promoter  region.    Positions  relative  to  
transcription  start  site  are  shown  to  the  right.    CpG-­island  probes  are  labeled  in  green.    Sample  order  in  bar  plots  and  methylation  heat  map  
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activation  of  STAT  transcription  factors,  which  we  also  see  
induced  by  AZA  (Fig.  1E).    
AZA  Alters   the   Immuno-­phenotype   of  NSCLC  
Through  Its  Effect  on  DNA  Methyltransferases
A   key   issue   for   all   of   the   above   responses   is  
whether  these  represent  attributes  of  AZA  as  a  targeted  
therapy.   In   this   regard,   this   drug,   particularly   at   less  
WR[LF GRVHV VSHFL¿FDOO\ WDUJHWV WKH WKUHH ELRORJLFDOO\
active  DNMT’s,  acting  to  directly  inhibit  their  catalytic  
sites   and   triggering   degradation   of   these   proteins   in  
the  nucleus  [9,  37].  We  thus  queried  how  our  complex,  
immune-­related,   pharmacologic   responses   compare  
to   simultaneous   genetic   depletion   of   two   of   the   three  
DNMT’s.  We  compared  HCT116  colon  cancer  cells  and  
HCT116  double  knock  out  (DKO)  cells   that  have  been  
JHQHWLFDOO\GLVUXSWHGWRJLYHVHYHUHKDSORLQVXI¿FLHQF\RI
DNMT1,  and  complete  absence  of  DNMT3B,  enzymes  
for   DNA  methylation   maintenance   and   de   novo   DNA  
methylation,  respectively[38].  These  cells  have   lost   the  
majority  of  their  genome-­wide  DNA  methylation  and  have  
GHPHWK\ODWLRQRIPDQ\FDQFHUVSHFL¿FSURPRWHUUHJLRQ
DNA  hypermethylated  CpG  islands  with  corresponding  
re-­expression  of  genes  silenced  in  the  wild  type  HCT  116  
cells  [38].  From  the  standpoint  of  the  present  studies,  the  
immune-­related   expression   alterations   in   DKO   versus  
wild   type  HCT116   are   remarkably   similar   to   the  AZA  
induced  changes  in  NSCLC  cells  (Fig.  2).  We  conclude  
that  previously  described  off  target  effects  of  high  dose  
AZA  including  incorporation  into  RNA  and  DNA  as  an  
abnormal  nucleotide[10]  do  not  appear  to  be  required  for  
WKHGUXJ¶VHIIHFWWKDWZHKDYHGH¿QHG
Up-­regulation  of  Immune  Related  Transcription  
Factors  by  Azacytidine
,Q RUGHU WR ¿QG VSHFL¿F JHQHV UHH[SUHVVHG LQ
response  to  AZA  which  may  be  driving  immune-­related  
FKDQJHV ZH H[WHQVLYHO\ ¿OWHUHG RXU JHQRPH ZLGH
expression  and  methylation  data  from  cell  line  experiments  
to   identify   transcription   factors   meeting   criteria   of  
epigenetically   re-­expressed   genes.   Approximately   300  
genes   with   high   baseline   promoter   region   CpG   island  
methylation,   promoter   demethylation   of   25%   or   more  
after  treatment,  and  expression  increased  by  log2  0.5  (1.4-­
fold)  or  greater  after  treatment  (Fig.  3A,  Supp.  Table  3).  
Nearly  17%  are   in   an   interferome  database[39]   (http://
www.interferome.org),  and  19%    are  transcription  factors  
[39,  40].  The  transcription  factor  IRF7  has  been  reported  
by  others  to  be  hypermethylated  in  cancer,  as  it  is  in  our  
NSCLC  line  with  the  lowest  basal  expression  [11,  40-­42].  
It  is  up-­regulated  in  response  to  AZA  in  several  cell  lines,  
most  prominently  in  the  LUSC  cell  line  H2170,  showing  
a  9-­fold  increase  (Fig.  1J).  IRF7  is  an  upstream  activator  
of   functions   in  cellular  pathways   recognizing   the  virus  
response   element   VRE-­A   to   increase   transcription   of  
genes  involved  in  type  1  IFN  signaling  [11].  There  is  a  
VLJQL¿FDQWDVVRFLDWLRQRIIRF7  transcription  targets  with  
genes  driving  several  of  our  GSEA  enrichment  scores  for  
the  immune  pathway  alterations  observed  in  response  to  
AZA  (Fig.  3B).  
Immune-­Phenotypes   within   Histologies   in   The  
Cancer  Genome  Atlas
From   our   analysis   suggesting   IRF7   to   be   a  
SRWHQWLDOO\ LPSRUWDQW FDQFHUVSHFL¿F K\SHUPHWK\ODWLRQ
induced   down-­regulation   event,   we   sought   to   create   a  
list  of  functionally  derived  genes  closely  associated  with  
its  re-­expression.  Examining  H2170,  the  LUSC  cell  line  
with  the  greatest  up-­regulation  of  IRF7  we  hypothesized  
that  other  genes  highly  up-­regulated  in  this  cell  line  might  
be  targets  of  this  transcription  factor  (Fig.  1J).  Filtering  
expression  array  data,  114  genes  where  found  to  be  4-­fold  
or  more  up-­regulated  in  response  to  AZA  in  the  H2170  
(Supp.   Table   4).   The   association   of   this   functionally  
derived  gene  list  with  IRF7LVFRQ¿UPHGE\36FDQDQDO\VLV
(p  =  7.6  e  -­18)  (Fig.  3B).  These  data  suggest  that  IRF7  
silencing  by  DNA  methylation  in  tumors  could  result  in  
suppression  of  immune-­regulatory  genes  important  for  the  
surveillance  of  tumors  by  cytotoxic  immune  mechanisms.  
Other  studies  have  reported  an  immune-­evasion  signature  
dependent  on  IRF7  in  breast  and  melanoma  [40,  43].  To  
test  if  such  relation  between  IRF7  and  immune-­regulatory  
genes   exist   in   primary   LUAD   and   LUSC   tumors,   we  
analyzed  the  expression  of  these  genes  as  a  function  of  
IRF7   expression,   and   its   promoter   methylation   status.  
We  found  that  low  expression  of  these  genes  describes  a  
subgroup,  particularly  among  LUSC,  in  TCGA  samples  
which   clusters   tightly  with  high  promoter   region  DNA  
methylation  and  low  expression  of  IRF7  (Figs.  3C,  3D,  
and  4).  Finally,  expression  levels  of  PD-­L1,  the  key  tumor  
ligand   targeted   in   the   anti-­checkpoint   immunotherapy  
trials,  tracks  quite  well  with  the  above  immune  evasion  
signature  in  subgroups  of  not  only  LUSC,  but  also  LUAD,  
as  especially  well  visualized  in  heat  maps  for  individual  
immune  related  pathways,  which  each  track  closely  with  
an  immune  evasion  signature  in  the  LUSC  and  LUAD,  
TCGA  samples  (Fig.  4).
DISCUSSION
In   the   present   work,   we   have   used   an   in-­vitro  
model   to   derive   a   pre-­clinical   understanding   of   the  
immunomodulatory  effects  of  clinically  relevant  doses  of  
AZA  in  NSCLC  that  may  underpin  its  potential  to  “prime”  
for  subsequent  response  to  PD-­1  pathway  blockade.  We  
characterize   an   AZA   induced   expression   signature   of  
immune  genes  and  pathways  in  NSCLC  known  to  play  
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)LJXUH  5HODWLRQVKLS RI D]DF\WLGLQHLQGXFHG LPPXQHUHODWHG SDWKZD\V WR SULPDU\ OXQJ WXPRUV JURXSHG E\
expression  of  IRF7-­associated  genes.  TCGA  samples  are  ordered  by  unsupervised  clustering  based  on  genes  highly  up-­regulated  in  
H2170,  which  are  enriched  for  IRF7-­targets,  represented  in  the  topmost  heat  map.  Order  of  samples  is  maintained  in  all  lower  heat  maps.  
3'/DQG,5)H[SUHVVLRQDUHGHSLFWHGLQWKHWRSEDUSDQHOVDVLQ¿JXUH'6XSSOHPHQWDO7DEOHWDEOHVKRZVWKHRYHUODSVRIJHQHVIURP
each  pathway  represented  in  the  heat  maps.  That  the  observed  clustering  pattern  is  not  due  to  chance  or  batch  effect  is  demonstrated  using  
random  sets  of  25  genes  shown  in  the  bottom  two  panels.
Lung Squamous Cell Carcinoma (TCGA)
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a   role   in   the   down-­regulation   of   immune   surveillance  
of  cancer.  However,   concomitant  with   induction  of   the  
immune   genes   comprising   both   innate   and   adaptive  
immunity   is   the   up-­regulation   of   a   primary   immune  
inhibitory   ligand,   PD-­L1.  Our   data   therefore   suggest   a  
mechanism  by  which  epigenetic  therapy  might  improve  the  
outcome  of  treatment  of  patients  with  NSCLC  with  PD-­1/
PD-­L1immune  checkpoint  blockade.  By  matching  these  
basal   gene   expression   and   DNA   methylation   patterns,  
including  that  of  a  core  interferon  pathway  transcription  
factor,  IRF7  in  the  TCGA  project,  we  extrapolate  our  in  
vitro  AZA-­induced  gene  signature  to  hundreds  of  primary  
NSCLC  cancers.  These  results  suggest  that  a  major  effect  
of   AZA   treatment   is   the   alteration   of   tumor   immune  
inducing,   pathways   that   could   lead   to   susceptibility   of  
tumor  cells  themselves  to  immune  attack  by  T  cells.  In  
particular,   because   the   inhibitory   ligand   PD-­L1   is   up-­
regulated  by  AZA  in  our  cell  lines,  and  subsets  of  primary  
tumors  have  concordant  low-­expression  of  AZA  induced  
immune  genes  and  PD-­L1,  we  suggest  that  combination  
of  epigenetic  therapy  and  PD-­1  pathway  blockade  might  
produce  a  synergistic  anti-­tumor  response.  
2XU ¿QGLQJV SURYLGH D EDVLV IRU ELRPDUNHU
approaches   that  we  will   test   in   a   just   initiated   trial   for  
patients   with   advanced   LUAD   and   LUSC,   aimed   at  
validating   the   promise   for   sensitization   by   epigenetic  
therapy   to   immune   checkpoint   therapy.   If  we   continue  
WRVHHUREXVWSDWLHQWHI¿FDF\RXUGDWDPD\SURYHNH\WR
GHWHUPLQLQJZKLFKLQGLYLGXDOVDUHOLNHO\WREHQH¿WIURP
the  epigenetic  therapy  approaches  we  are  testing  in  clinical  
trials  by  evaluating  gene  panels  for  expression  and  DNA  
methylation  in  pre-­and  post-­  drug  administration  biopsies.  
MATERIALS  AND  METHODS
Clinical  Data
Institutional   review   board   approved   informed  
consent  signed  by  each  patient  allowed  the  collection  of  
clinical  data  following  treatment  on  trial  with  epigenetic  
therapy.   Relevant   data   were   obtained   by   chart   review.  
Representative   images   demonstrating   responses   to  
therapy  were  obtained  from  computed  tomography  series  
employed  in  the  assessment  of  patient  responses  to  anti-­
PD1  or  anti-­PD-­L1  directed  immune-­checkpoint  therapy.  
Assessment  of  response  to  treatment  was  performed  by  
a   single   reference   radiologist  who   employed   (RECIST  
1.0)   to   generate  measurements   for   target   lesions   to   be  
followed   over   the   course   of   therapy.   Change   in   target  
lesions  from  baseline  (%)  is  calculated  by  summing  the  
diameter  of  all  target  lesions  at  each  radiographic  tumor  
evaluation  and  calculating  percentage  change  at  a  given  
time   point   ([(Target   Lesion   SumTimepoint   X/   Target  
Lesion  SumBaseline)-­1]*100).
TCGA  Samples
Level  3  RNA-­Seq  data  (Illumina  HiSeq  RNA-­Seq  
platform,   Illumina,   Inc.,   San   Diego,   CA,   USA)   were  
downloaded  for  353  NSCLC  samples  (129  LUAD  /  224  
LUSC)  and  54  adjacent  non-­tumor   lung   tissue  samples  
from  the  TCGA  Data  Portal  (https://tcga-­data.nci.nih.gov/
tcga/).  Similarly,  level  1  DNA  methylation  data  (Illumina  
,Q¿QLXP+XPDQ0HWK\ODWLRQ%HDG&KLS,OOXPLQD,QF
San  Diego,  CA,  USA)  were  downloaded  for  353  NSCLC  
samples  (222  LUAD  /  149  LUSC)  and  74  adjacent  non-­
tumor   lung   tissue   samples.  Among   these,   data   for   174  
NSCLC  samples  (80  LUAD  /  94  LUSC)  and  21  adjacent  
non-­tumor  lung  tissue  samples  were  available  on  both  of  
the  above  platforms.
RNA-­Seq  Data  Analysis
We   used   TCGA   level   3   RNA-­Seq   data   already  
QRUPDOL]HGDQGTXDQWL¿HGDWJHQHOHYHOVDQGSUHVHQWHG
as   RPKM   values   (Reads   Per   Kilobase   per   Million  
mapped  reads).  To  construct  heat  maps:  1)  Values  of  0  
(indicating  no  reads  observed  for  a  gene)  in  the  RPKM  
data  were  set  to  NA;;  2)  the  remaining  RPKM  values  were  
log  2  transformed;;  3)  genes  from  X  and  Y  chromosomes  
were   removed;;   and   4)   heat   maps   were   made   using  
the   “heatmap.2”   function   in   “gplots”   package   from  
CRAN[44]being  centered  and  scaled  in  the  row  direction,  
and  using   the  default   functions   for   computing  distance  
DQGKLHUDUFKLFDOFOXVWHULQJRUEHLQJVSHFL¿FDOO\RUGHUHG
in   column   according   to   the   order   of   other   heat  maps).  
Expression  spectrums  for  individual  genes  were  displayed  
LQ¿YHTXDUWLOHLQWHUYDOVIROORZLQJWKHRUGHURIDVVRFLDWHG
heat  maps  of  the  RNA-­Seq  data.  
,Q¿QLXP'1$0HWK\ODWLRQ'DWD$QDO\VLV
TCGA  level  1  DNA  methylation  data  contain  raw  
ELQDU\LQWHQVLW\GDWD¿OHV5DZGDWD¿OHVZHUHLPSRUWHG
into  R  (http://www.r-­project.org)  to  calculate  beta  values  
EHWDYDOXH,Q¿QLXP 0>80@0PHDQLQWHQVLWLHV
of  the  Methylated  bead  type,  U:  mean  intensities  of  the  
8QPHWK\ODWHGEHDGW\SHV0YDOXHV0YDOXH,Q¿QLXP
=  log  2  [M  /  U])  and  detection  p-­values  (calculated  by  
comparing  probes  to  negative  control  probes  to  determine  
LIVLJQDOVDUHVLJQL¿FDQWO\GLIIHUHQWIURPWKHEDFNJURXQG
using  the  “methylumi”  package  from  Bioconductor  [45].  
Beta   values   and   M   values   for   probes   with   detection  
SYDOXH!ZHUHFRQVLGHUHGQRWVLJQL¿FDQWO\GLIIHUHQW
from   background   and   were   masked   as   NA.   TCGA  
PHWK\ODWLRQGDWDZHUH¿UVWDVVHVVHGIRUEDWFKHIIHFWVE\
principle  component  analysis  (PCA)  on  the  M  values.  To  
accomplish  this,  data  points  from  X  chromosome  and  Y  
chromosome   as  well   as   data   points   that   are   associated  
Oncotarget10www.impactjournals.com/oncotarget
with   SNPs   (Single   Nucleotide   Polymorphisms)   were  
UHPRYHGDQGWKH¿UVWWZRSULQFLSOHFRPSRQHQWVDUHXVHG
for  plotting.  
6SHDUPDQ¶V FRUUHODWLRQ FRHI¿FLHQWV EHWZHHQ
PHWK\ODWLRQ EHWD YDOXH RI SUREH ,OOXPLQD ,Q¿QLXP
HumanMethylation450  BeadChip)  and  gene  expression  
(RPKM   value   of   gene,   Illumina   HiSeq   RNA-­Seq  
platform)   were   calculated   using   TCGA   samples   with  
available  data  on  both  platforms.  For  a  particular  gene,  
only  methylation  probes  that  have  a  negative  Spearman’s  
FRUUHODWLRQFRHI¿FLHQWDQGDDGMXVWHGSYDOXH)'5IRU
WKHFRHI¿FLHQWZHUHFRQVLGHUHG LQIRUPDWLYHDQG
their  relative  distances  to  the  corresponding  transcriptional  
start  site  (TSS)  of  the  genes  were  calculated  from  genomic  
coordinates   obtained   from   the  UCSC   genome   browser  
(http://genome.ucsc.edu).  Heat  maps  of  the  M  values  of  
informative   probes   were   made   using   the   “heatmap.2”  
function   in   “gplots”   package   from   CRAN[44]   being  
centered   and   scaled   in   the   row   direction,   and   ordered  
according   to   the  associated  heat  maps  of   the  RNA-­Seq  
data  in  column  and  to  the  relative  distances  to  TSS  in  row.
For   in   vitro  DNA  methylation   values,   DNA  was  
extracted   from   cell   lines   that   were   either   untreated   or  
treated  with  AZA  at  day  3,  at  the  end  of  treatment,  and  
day  10  (7  days  post  end  of   treatment)  and  analyzed  by  
WKH,OOXPLQD,Q¿QLXP+XPDQ0HWK\ODWLRQ%HDG&KLSV
(Illumina,   Inc.,  San  Diego,  CA,  USA).  Raw  data  were  
imported   into   R   using   the   “methylumi”   package   from  
Bioconductor  [45].  Data  points  for  probes  with  detection  
SYDOXH ! ZHUHPDVNHG DV 1$ǻ EHWD YDOXHV ǻ
beta  value  =  beta  value  AZA  –  beta  value  Mock)  were  
calculated  and  used  to  make  boxplots.  Heat  maps  were  
made   similarly   like   those   for   the   TCGA   data   using  
LQIRUPDWLYHSUREHVGH¿QHGE\WKH7&*$GDWD
Expression  Microarray  Data
For  in-­vitro  RNA  extracted  from  cell  lines  treated  
with  AZA,  analyses  were  done  at  exactly  the  same  time  
points  as  for  DNA  methylation  above.  Analyses  from  wild  
type  colon  cancer,  HCT116  cells,  and  genetic  knockout  
counterparts   for   DNA   methyltransferases   (DKO   cells)  
were   also   performed.   Expression   microarrays   were  
carried  out  using  Agilent  Human  4×  44K  expression  arrays  
(Agilent   Technologies,   Santa   Clara,   CA,   USA,   Cat#:  
G4112F).  Within-­array  and  between  -­  array  normalization  
was  performed  using  Loess  and  Aquantile  normalization,  
respectively[46].   Median   of   the   M   values   (M   value  
Expression   =   log   2   [AZA   /  Mock]   OR   log   2   [DKO   /  
HCT116])  was  determined  for  multiple  probes  associated  
with  the  same  gene.
Gene  Set  Enrichment  Analysis  (GSEA)
For  each  of  the  eight  lung  cancer  cell  lines  (H838,  
H1299,  H358,  H1270,  A549,  H460,  HCC4006,  HCC827)  
a   ranked   gene   list   was   created   (genes   were   sorted   by  
decreasing  M  value).  These  eight  ranked  gene  lists  were  
entered  in  the  GSEA  tool[47,  48]and  the  enrichment  of  
both   Kegg   [49]   and   Reactome[50]   pathways   in   these  
lists  was  calculated  (default  parameters).  A  gene  set  was  
selected  when   it  was   enriched   in   any   of   the   eight   cell  
OLQHVSYDOXHDQGIDOVHGLVFRYHU\UDWH7KH
normalized  enrichment  scores  (NES)  for  the  gene  sets  in  
each  cell  line  were  used  to  create  the  heat  maps.  When  a  
FHUWDLQJHQHVHWZDVQRWVLJQL¿FDQWLQDFHOOOLQHLWZDV
assigned  a  NES  of  0.
Transcription  Factor  Analysis
Expression   and   methylation   data   were   analyzed  
WR ¿QG JHQHV ZKRVH UHH[SUHVVLRQ ZDV OLQNHG WR
demethylation  after  AZA  treatment.  Genes  were  selected  
based  on  a  set  of  cut-­offs,  both  for  the  methylation  and  
expression   values:   A   gene   was   considered   to   be   re-­
expressed  when  at  day  3  or  day  10  the  median  M  value  
of  all  the  probes  linked  to  that  gene  was  higher  than  0.5.  
,Q¿QLXPSUREHVZHUHDQDO\]HGVHSDUDWHO\DWWKHLUGLVWDQFHV
from  the  transcription  start  site  for  each  gene  examined.  
For  a  probe  to  be  called  demethylated,  it  had  to  have  a  
beta  value  higher  than  0.5  in  the  mock  treatment  and  a  
difference  in  beta  value  between  mock  and  AZA  treatment  
had  to  be  at  least  0.25.  Only  probes  that  were  associated  
with  a  CpG  island  and  that  were  located  within  1000  bp  
upstream  and  1000  bp  downstream  of   the   transcription  
start  site  were  used  in  the  analyses.  The  probes  that  passed  
WKHVH¿OWHUVZHUHYDOLGDWHGXVLQJWKH7&*$PHWK\ODWLRQ
DQG H[SUHVVLRQ GDWD VHH WKH GH¿QLWLRQ RI LQIRUPDWLYH
SUREHVLQWKH³,Q¿QLXP'1$0HWK\ODWLRQ'DWD´VHFWLRQRI
Methods).  Only  genes  that  had  an  expression-­methylation  
FRUUHODWLRQ YDOXH   DQG D IDOVH GLVFRYHU\ UDWH 
0.05  were   retained.  To  better  understand   the  biological  
implications   of   the   re-­expressed   genes,   the   gene   lists  
were   searched   for   transcription   factors.   Two   human  
transcription  factor  lists  obtained  from  Ravasi  et  al  [51]and  
Vaquerizas  et  al  [52,  53]  were  combined  and  the  resulting  
list   was   matched   to   the   lists   of   demethylated   and   re-­
expressed  genes.  The  targets  of  IRF7  from  the  list  of  genes  
that  are  4-­fold  or  more  up-­regulated  in  H2170  by  AZA  
ZHUHVLPLODUO\LGHQWL¿HGXVLQJWKH7UDQVFULSWRPH%URZVHU
database  [54].
Flow  Cytometry  Methods  (FACS)




labeled  antibodies  for  15  minutes  at   room  temperature.  
Each   sample   was   washed   twice   and   re-­suspended   in  
ÀRZZDVKLQJ EXIIHU DQG DQDO\]HG E\ )$&6&DOLEXU
The  following  antibodies  were  used:  CD274  (12-­5983-­
42  Ebiosciences),  HLA  abc  (12-­9983-­42  Ebiosciences),  
CD276(331606   Biolegend),   CD119(558934   BD),   B2  
microblogumin(551337BD),  CD58(555921BD).    Changes  
between  AZA  treated  and  mock  cells  are  calculated  using  
PHDQ ÀXRUHVFHQFH LQWHQVLWLHV 0), DQG WKH IRUPXOD
log2([(MFIantibody,  treated)-­(MFIisotype,  treated)]/  [(MFIantibody,  mock)-­
(MFIisotype,  mock)]).
PSCAN
PSCAN   (http://159.149.160.51/pscan/)   [55]   is   an  
online  software  tool  that  predicts  the  association  of  user  
GH¿QHGJHQHOLVWVZLWKWUDQVFULSWLRQIDFWRUVE\VFDQQLQJ
promoter  sequences  of  co-­regulated  or  co-­expressed  genes  
looking  for  over-­  or  under-­represented  motifs.  RefSeq  IDs  
of  the  gene  lists  were  obtained  from  BioMart  (http://www.
biomart.org/)  and  analyzed  in  PSCAN.  Scanned  promoter  
UHJLRQZDVWREDVHSDLUVDURXQGWKHWUDQVFULSWLRQ
start  site  and  employing  TRANSFAC  as  the  database  for  
co-­regulated  or  co-­expressed  genes.
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